Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05032040 · ClinicalTrials.gov registry record · Phase 2
A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies
A Phase 2 study of Ovarian Cancer and Endometrial Cancer, sponsored by Xencor.
- Active
- Registry status
- Phase 2
- Development phase
- 170
- Enrollment target
- 17
- Study locations
NCT05032040: Active Phase 2 study of Ovarian Cancer and Endometrial Cancer, sponsored by Xencor.
NCT05032040 is a Phase 2 study of Ovarian Cancer and Endometrial Cancer that is active but no longer recruiting, run by Xencor. The registered enrollment target is 170 participants, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (77% lower). The trial reports 17 study locations across 12 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05032040, a Phase 2 study of Ovarian Cancer and Endometrial Cancer, is active but no longer recruiting, sponsored by Xencor.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 170 participants
- Enrollment target
- 17
- Study locations
Study Summary
This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
Conditions Studied
Interventions
- BIOLOGICAL vudalimab
Study Locations (17)
California
- UCSD Moores Cancer Center - La Jolla
- Valkyrie Clinical Trials - Los Angeles
- UCLA Medical Center - Los Angeles
- Kaiser Permanente Medical Group - Riverside
- UCSF Helen Diller Family Comprehensive Cancer Center - San Francisco
New York
- NYU Langone Health - New York
- Columbia University Medical Center - New York
Arizona
- Arizona Oncology Associates, PC - NAHOA - Prescott
Colorado
- Rocky Mountain Cancer Centers - Aurora
Delaware
- Medical Oncology Hematology Consultants, PA - Newark
Florida
- Moffitt Cancer Center - Tampa
Georgia
- Winship Cancer Institute, Emory University - Atlanta
Michigan
- Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 170 participants |
| Start Date | 2022-07-21 |
| Est. Completion | 2025-12-30 |
| Phase | Phase 2 |
What the registry record for NCT05032040 still lists
NCT05032040 is an interventional study that assigns participants to a tested intervention. The registered 170 participants enrollment target is mid-sized for trials with a published cap, below the 728-participant average among 322 other Ovarian Cancer trials with a reported enrollment target (77% lower).
The record links to 5 conditions, with Ovarian Cancer appearing as the primary indexed condition, and to 1 intervention - of which vudalimab is the first listed.
NCT05032040 lists 17 locations in 12 states (California, New York, Arizona).
Frequently Asked Questions
What is clinical trial NCT05032040 about?
NCT05032040 is a clinical study titled "A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies". This is a Phase 2, multicenter, two-stage, open-label, parallel-group study designed to evaluate the efficacy and safety of vudalimab (XmAb20717) in patients with selected advanced gynecologic and genitourinary malignancies.
What is the current status of trial NCT05032040?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 170 participants. The study started on 2022-07-21. Estimated completion is 2025-12-30.
What conditions does trial NCT05032040 study?
This clinical trial studies the following conditions: Ovarian Cancer, Endometrial Cancer, Cervical Carcinoma, Metastatic Castration-Resistant Prostate Cancer (mCRPC), Clear Cell Carcinoma.
What interventions are being tested in trial NCT05032040?
The interventions under investigation include: vudalimab (BIOLOGICAL).
Who is sponsoring clinical trial NCT05032040?
This trial is sponsored by Xencor, which has 27 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05032040 being conducted?
This trial has 17 study locations across Arizona, California, Colorado, Delaware, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ovarian Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05032040's enrollment target sits among peer trials
170 112th of 322 higher than 209 of 322 other Ovarian Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Ovarian Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
ZEN003694 Combined With Talazoparib in Patients With Recurrent Ovarian Cancer
RECRUITING · Phase 2
-
A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery
RECRUITING · Phase 2
-
Decitabine and Selinexor in Combination to Reverse Drug Resistance With Standard Chemotherapy in Ovarian Cancer
RECRUITING · Phase 2
-
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Secondary Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Recurrent Mucinous Ovarian Cancer (HI-MOC Study)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
- NCT04166409 · 170 participants · Phase 3
A Study of the Drugs Selumetinib vs. Carboplatin and Vincristine in Patients With Low-Grade Glioma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI